Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer

Study acronym: GEMCOL
StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 4 words
  2. 2 versions Re-verified since Jul 23, 2012, no change to tracked fieldsv4-v5
  3. Interventions: Cisplatine (Drug), Gemcitabine (Drug), Radiotherapy (Procedure) to Cisplatin (Drug), Gemcitabine (Drug), Radiotherapy (Procedure)
    • Eligibility criteria revised
    • Study description shortened, about 9 words
    • Study arms: 0 to 1
    v3
  4. Trial status: Recruiting to Terminated Sponsor's reason: Problems of recruitmentv2 Show 5 more changesShow less
    • Enrollment target: 73 to 19
    • Primary completion date: Apr 2008
    • Study completion date: May 2013 to Dec 2011
    • Secondary endpoints: 1 to 2
    • Site details revised at 2 of 2 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The scope of the trial is to assess the efficacy of the association gemcitabine-cisplatin + radiotherapy followed by an adjuvant chemotherapy
Trial Details
NCT Number NCT00421096
Lead Sponsor Centre Oscar Lambret
Conditions
(from sponsor)		 Uterine Cervical Cancer
Related terms Uterine Cervical Neoplasms
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov